Johnson & Johnson trades around $257, close to its 52-week high and a long way from last year's low near $154. The story splits cleanly in two. One side sees a healthcare giant heading for its first $100 billion sales year, backed by a 64-year dividend streak. The other sees a fading blockbuster, a giant legal bill, and a price that has run ahead of what most analysts think the stock is worth.
Both cases are real. Here is where each one stands.
The Bull Case Starts With Drugs
J&J's Innovative Medicine unit is doing the heavy lifting. First-quarter 2026 sales rose about 10% to $24.1 billion, and the drug business grew faster than that at 11%. Management raised full-year guidance to a range of $100.3 billion to $101.3 billion, which would clear $100 billion in annual sales for the first time in company history.
Cancer drugs lead the charge. Darzalex, J&J's single biggest product, posted first-quarter sales of nearly $4 billion, up 22% from a year earlier. The company wants its oncology portfolio to reach $50 billion in yearly sales by the end of the decade, double the roughly $25 billion it booked in 2025.
The immunology pipeline backs it up. Tremfya cleared $1.6 billion in the first quarter alone after new approvals in Crohn's disease and ulcerative colitis. Spravato, a nasal-spray depression treatment, grew 57% last year to $1.7 billion, and J&J is now rolling out a new psoriasis pill. That fresh growth is the engine bulls are counting on to replace older products as they age.
A Dividend Built to Last
For income investors, J&J is one of the steadiest names on the market. The company raised its dividend for the 64th straight year in April 2026, lifting the quarterly payout to $1.34 a share, or $5.36 a year. That works out to a yield just over 2% at the current price, modest on its own but attached to one of the most reliable payout records in the market.
The balance sheet is a big part of the appeal. J&J holds a top-tier AAA credit rating, one of only two U.S. companies that still does. With a market value near $620 billion and steady cash flow, it is the kind of stock that tends to hold up when the broader market sells off.
MedTech, the other half of the business, adds ballast. The unit sells surgical tools, heart devices, and orthopedic implants, and it grew about 8% in the first quarter. Two large, profitable divisions give J&J more ways to grow than a pure drug company has.
The Bear Case Starts With Stelara
Now the other side. J&J's former top seller, the immune drug Stelara, is falling off a cliff. First-quarter Stelara sales dropped 60% to $656 million as cheaper biosimilar copies from rivals like Amgen and Teva flooded in. Full-year 2025 sales had already fallen 41%.
The pressure is building, not easing. A Medicare price negotiation under the Inflation Reduction Act targets Stelara for a steep cut, and starting July 1, 2026, CVS Health Caremark shifted its main commercial drug lists to prefer those cheaper biosimilars over Stelara. Every dollar Stelara loses is a dollar the newer drugs have to replace before J&J shows real growth on the bottom line.
The Talc Cloud
The bigger overhang is legal. J&J faces roughly 68,000 lawsuits claiming its talc-based baby powder caused ovarian cancer, a link the company denies. A plan to settle the claims for about $9 billion through a bankruptcy filing was rejected by a judge, so the cases are now moving through the regular court system.
The results have been mixed. J&J lost a $40 million verdict in late 2025 but won a California trial in June 2026. One Wall Street estimate pegs the eventual cost as high as $11 billion, and a federal judge has cleared plaintiffs' experts to argue the cancer link in court. Until a final number is set, the talc fight hangs over the stock as an open-ended risk that no earnings beat can fully erase.
The Price Is the Catch
Valuation is where the two cases collide. At around $257, J&J trades at roughly 22 times this year's expected adjusted earnings of about $11.55 a share. That is a clear premium to the low-to-mid-teens multiple the stock carried for much of the past decade, and it means investors are already paying up for the growth story.
Wall Street is not chasing it. The average analyst price target sits near $240, below where the stock trades now, even though the most bullish call reaches $280. When the crowd's average target is under the current price, the market has already baked in a lot of the good news.
What to Watch Next
The next few quarters will decide which case wins. The key test is whether oncology and immunology growth can keep outrunning the Stelara decline long enough to carry J&J past $100 billion in sales and beyond. A resolution on talc, most likely a broad settlement, would remove the single biggest unknown and could re-rate the stock on its own.
A name sitting near record highs with a below-market analyst target leaves little room for error. That tension is exactly why both the bull and the bear deserve a hearing before anyone commits new money here.
